MARKET

ANIX

ANIX

Anixa Biosciences Inc
NASDAQ
4.360
+0.050
+1.16%
Closed 16:00 03/24 EDT
OPEN
4.260
PREV CLOSE
4.310
HIGH
4.390
LOW
4.110
VOLUME
38.36K
TURNOVER
99.49K
52 WEEK HIGH
6.25
52 WEEK LOW
2.500
MARKET CAP
134.83M
P/E (TTM)
-9.7365
1D
5D
1M
3M
1Y
5Y
--HC Wainwright Adjusts Price Target on Anixa Biosciences to $12 From $11, Keeps Buy Rating
--HC Wainwright Adjusts Price Target on Anixa Biosciences to $12 From $11, Keeps Buy Rating
MT Newswires · 3d ago
Chardan Capital Sticks to Its Buy Rating for Anixa Biosciences (ANIX)
TipRanks · 3d ago
Chardan Capital Maintains Buy on Anixa Biosciences, Raises Price Target to $9
Benzinga · 4d ago
--Chardan Adjusts Price Target on Anixa Biosciences to $9 From $8, Keeps Buy Rating
--Chardan Adjusts Price Target on Anixa Biosciences to $9 From $8, Keeps Buy Rating
MT Newswires · 4d ago
BRIEF-Anixa Biosciences Reassures Shareholders It Has No Accounts At Silicon Valley Bank
Reuters · 03/13 13:05
H.C. Wainwright Keeps Their Buy Rating on Anixa Biosciences (ANIX)
TipRanks · 02/28 11:25
HC Wainwright & Co. Reiterates Buy on Anixa Biosciences, Maintains $11 Price Target
Benzinga · 02/28 11:08
Anixa Biosciences Receives Patent Allowance Notice For Breast Cancer Vaccine Technology
Anixa Biosciences Receives Patent Allowance Notice For Breast Cancer Vaccine Technology
MT Newswires · 02/27 11:40
More
About ANIX
Anixa Biosciences, Inc. is a biotechnology company. The Company is primarily engaged in developing vaccines and therapies that are focused on critical unmet needs in oncology and infectious disease. The Company's segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Others. Its vaccine programs include the development of a preventative vaccine against triple-negative breast cancer (TNBC), the lethal form of breast cancer, as well other forms of breast cancer, and the development of a preventative vaccine against ovarian cancer. Its therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a form of chimeric antigen receptor T-cell (CAR- T) technology that is focused on treating ovarian cancer, which is developed at its subsidiary, Certainty Therapeutics, Inc., and the development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus.

Webull offers kinds of Anixa Biosciences Inc stock information, including NASDAQ:ANIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANIX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANIX stock methods without spending real money on the virtual paper trading platform.